Evolent Health (EVH) Tops Q1 EPS by 5c, Offers Guidance
Evolent Health (NYSE: EVH) reported Q1 EPS of ($0.01), $0.05 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $215.1 million versus the consensus estimate of $212.79 million.
GUIDANCE:
Evolent Health sees Q2 2021 revenue of $210-225 million, versus the consensus of $212 million.
Evolent Health sees FY2021 revenue of $845-880 million, versus the consensus of $865 million.
For earnings history and earnings-related data on Evolent Health (EVH) click here.
